{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:06:58Z","timestamp":1789538818262,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    Typically, colorectal carcinoma (CRC) is morphologically relatively homogeneous. Uncommon morphologic patterns may be enriched for rare molecular drivers. This study examined the clinicopathologic characteristics of CRC with multivergent morphology (defined as 2 discrete nonconventional morphologic cytoarchitectural patterns) and whether potentially targetable molecular alterations could be identified by interrogating 2 distinct morphologic areas. Evaluation of representative sections from 213 consecutive CRC resections identified 11 with multivergent morphology. Next-generation sequencing (NGS) was performed on 2 morphologically discrete areas from multivergent cases. Compared with the remaining 202 CRCs, multivergent CRCs were larger (mean: 6.4 vs. 4.4\u00a0cm;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.038), had a higher T stage (100% vs. 78.2% \u2265T3;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =5.0\u00d710\n                    <jats:sup>\u22124<\/jats:sup>\n                    ), a higher N stage (90.9% vs. 42.1% \u2265N1,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =7.0\u00d710\n                    <jats:sup>\u22124<\/jats:sup>\n                    ), and more frequently had distant metastasis (36.4% vs. 10.9%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.041). Multivergent CRCs were more likely to be mismatch repair (MMR)-deficient (45.5% vs. 15.8%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.034) and to have an atypical MMR pattern (27.3% vs. 0.5%;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =1.7\u00d710\n                    <jats:sup>\u22127<\/jats:sup>\n                    ). Both areas of multivergent CRC often harbored molecular alterations associated with eligibility for Food and Drug Administration (FDA)-approved therapies (63.6%; 7\/11) and clinical trials (72.7%; 8\/11). Not uncommonly, a molecular alteration associated with eligibility for FDA-approved therapy (45.5%; 5\/11) and clinical trials (72.7%; 8\/11) was isolated to only one of the sequenced areas. Multivergent CRC is rare but associated with targetable molecular alterations. NGS of multiple areas with different morphologies may help identify potential therapeutic targets. While most cases have recognizable driver alterations, the less common, targetable alterations identified in these cases could open additional trial options for salvage therapy.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002582","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:01:04Z","timestamp":1784880064000},"page":"1195-1204","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Sequencing of Multivergent Morphologies in Colorectal Carcinomas Identifies Unique Targetable Alterations"],"prefix":"10.1097","volume":"50","author":[{"given":"Brent K.","family":"Larson","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Makhoul","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gangi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Guindi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hendifar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hutchings","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kozak","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Osipov","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vail","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Waters","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"e240029","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41431-017-0067-1","article-title":"Phenotypic characteristics of colorectal cancer in BRCA1\/2 mutation carriers","volume":"26","author":"Grinshpun","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"R4-20260916","first-page":"6421205","article-title":"Mucinous histology, BRCA1\/2 mutations, and elevated tumor mutational burden in colorectal cancer","volume":"2020","author":"Harpaz","year":"2020","journal-title":"J Oncol"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41379-019-0417-3","article-title":"NTRK gene rearrangements are highly enriched in MLH1\/PMS2-deficient, BRAF wild-type colorectal carcinomas: a study of 4569 cases","volume":"33","author":"Chou","year":"2020","journal-title":"Mod Pathol"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/PAS.0000000000001377","article-title":"Colonic adenocarcinomas harboring NTRK fusion genes: a clinicopathologic and molecular genetic study of 16 cases and review of the literature","volume":"44","author":"Lasota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1002\/cam4.2344","article-title":"Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene","volume":"8","author":"Hino","year":"2019","journal-title":"Cancer Med"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/his.13984","article-title":"Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase \u03b5 (POLE)","volume":"76","author":"Forg\u00f3","year":"2020","journal-title":"Histopathology"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13148-021-01104-7","article-title":"Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations","volume":"13","author":"Kawai","year":"2021","journal-title":"Clin Epigenetics"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/oncolo\/oyad315","article-title":"A somatic BRCA2-mutated pancreatic adenocarcinoma with sustained exceptional response to modified FOLFIRINOX","volume":"29","author":"Jamison","year":"2024","journal-title":"Oncologist"},{"key":"R11-20260916","first-page":"e26648","article-title":"Larotrectinib in mismatch-repair-deficient TRK fusion-positive metastatic colon cancer after progression on immunotherapy","volume":"14","author":"Kasi","year":"2022","journal-title":"Cureus"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.humpath.2020.03.002","article-title":"Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?","volume":"98","author":"Lin","year":"2020","journal-title":"Hum Pathol"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ajcp\/aqab023","article-title":"IDH1 and IDH2 mutations in colorectal cancers","volume":"156","author":"Huang","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ajcp\/aqab119","article-title":"Double PIK3CA alterations and parallel evolution in colorectal cancers","volume":"157","author":"Lin","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","article-title":"Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discov"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3390\/cancers13092148","article-title":"Discordance of KRAS mutational status between primary tumors and liver metastases in colorectal cancer: impact on long-term survival following radical resection","volume":"13","author":"Ardito","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3390\/cancers12102938","article-title":"Clonal evolution and timing of metastatic colorectal cancer","volume":"12","author":"Siraj","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41586-022-05311-x","article-title":"Phenotypic plasticity and genetic control in colorectal cancer evolution","volume":"611","author":"Househam","year":"2022","journal-title":"Nature"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"eaay9691","DOI":"10.1126\/sciadv.aay9691","article-title":"The clonal evolution of metastatic colorectal cancer","volume":"6","author":"Dang","year":"2020","journal-title":"Sci Adv"},{"key":"R23-20260916","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1746-1596-9-126","article-title":"Heterogeneous mismatch-repair status in colorectal cancer","volume":"9","author":"Joost","year":"2014","journal-title":"Diagn Pathol"},{"key":"R24-20260916","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cjp2.120","article-title":"Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation","volume":"5","author":"McCarthy","year":"2019","journal-title":"J Pathol Clin Res"},{"key":"R25-20260916","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jclinpath-2018-205687","article-title":"Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation","volume":"72","author":"Westwood","year":"2019","journal-title":"J Clin Pathol"},{"key":"R26-20260916","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s40425-019-0788-5","article-title":"Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI\/dMMR status","volume":"7","author":"Loupakis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.modpat.2022.100012","article-title":"Unique patterns of heterogeneous mismatch repair protein expression in colorectal cancer unveil different degrees of tumor mutational burden and distinct tumor microenvironment features","volume":"36","author":"Berrino","year":"2023","journal-title":"Mod Pathol"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"djx089","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/cam4.1245","article-title":"POLE somatic mutations in advanced colorectal cancer","volume":"6","author":"Guerra","year":"2017","journal-title":"Cancer Med"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.5081","article-title":"Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response","volume":"245","author":"Temko","year":"2018","journal-title":"J Pathol"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy","volume":"12","author":"Dworak","year":"1997","journal-title":"Int J Colorectal Dis"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:00:20Z","timestamp":1789538420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002582","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"2025-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}